Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Views
    • Webinars
    • PharmSci360
  • Pharma 50
    • 2026 Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertisers
    • Advertise
    • PR Submissions
    • Eblast Submissions
  • SUBSCRIBE

Newly Discovered Antibiotic Show Promise in Drug Resistance Fight

By Kenny Walter | April 6, 2018

A new class of antibiotics that binds to ribosome and disrupts protein synthesis could be the next tool targeting the growing threat of drug resistant bacteria.

An international team led by researchers from the University of Illinois at Chicago and Nosopharm, a biotechnology company based in Lyon, France, discovered that symbiotic bacteria, found in soil-dwelling nematode worms that colonize insects for food produce, an antibiotic called odilorhabdins (ODLs).

The bacteria helps to kill the insect, while secreting the antibiotic to keep competing bacteria away.

The researchers screened 80 cultured strains of the bacteria for antimicrobial activity and then isolated the active compounds and studied their chemical structures. They then engineered derivatives that are more potent.

The team found that ODLs act on the ribosome—the molecular machine of individual cells that make the protein needed to function—of bacterial cells.

“Like many clinically useful antibiotics, ODLs work by targeting the ribosome, but ODLs are unique because they bind to a place on the ribosome that has never been used by other known antibiotics,” Yury Polikanov, an assistant professor of biological sciences in the UIC College of Liberal Arts and Sciences, said in a statement.

The team also found that when bound to the ribosome, the antibiotic disrupts its ability to interpret and translate genetic code.

“When ODLs are introduced to the bacterial cells, they impact the reading ability of the ribosome and cause the ribosome to make mistakes when it creates new proteins,” Alexander Mankin, director of the Center for Biomolecular Sciences in the UIC College of Pharmacy, said in a statement. “This miscoding corrupts the cell with flawed proteins and causes the bacterial cell to die.”

During the study, ODL compounds cured mice infected with several pathogenic bacteria and demonstrated activity against both Gram-negative and Gram-positive pathogens, including Carbapenem-resistant Enterobacteriacae, a family of germs that have high levels of resistance to antibiotics and are common in bloodstream and surgical site infections, contributing to death in up to 50 percent of patients who become infected.     

The antibiotic could be effective at treating both drug-resistant and hard-to-treat bacterial infections.

“The bactericidal mechanism of ODLs and the fact that they bind to a site on the ribosome not exploited by any known antibiotic are very strong indicators that ODLs have the potential to treat infections that are unresponsive to other antibiotics,” Mankin said.

According to the World Health Organization, antibiotic resistant is one of the biggest threats to global health today and a significant contributor to longer hospital stays, higher medical costs and increased mortality.

The study was published in Molecular Cell.   


Filed Under: Drug Discovery

 

Related Articles Read More >

Insilico’s AI-designed TEAD inhibitor shrank tumors in 4 of 22 mesothelioma patients; randomized Phase 2a planned for 2027
If Trump gets Europe to pay more for drugs, more new medicines could follow — eventually
Antibody - visual concept of immune System - 3D illustration
Fresenius picks the biosimilars, WuXi Biologics builds them in a deal covering up to 37 candidates
Physician in a white coat reviewing information on a tablet with a patient in an exam room.
What real-world data shows about current cancer care
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Drug Delivery Business News
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Pharmaceutical Processing World
  • R&D World
  • Subscribe to our E-Newsletter
  • About Us
  • Contact Us

Copyright © 2026 Arrowfly LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of Arrowfly
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Views
    • Webinars
    • PharmSci360
  • Pharma 50
    • 2026 Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertisers
    • Advertise
    • PR Submissions
    • Eblast Submissions
  • SUBSCRIBE